CytoMed Therapeutics

GDTC · NASDAQ

$0.919+$0.00 (+0.00%)TodayMarket closed ·
Prev close $0.919

Latest news

  • News

    12 Health Care Stocks Moving In Monday's After-Market Session

  • News

    12 Health Care Stocks Moving In Friday's After-Market Session

  • News

    12 Health Care Stocks Moving In Tuesday's Intraday Session

  • News

    12 Health Care Stocks Moving In Friday's Intraday Session

  • News

    12 Health Care Stocks Moving In Thursday's After-Market Session

  • News

    12 Health Care Stocks Moving In Friday's After-Market Session

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • News

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • NewsAvi Kapoor

    Why Align Technology Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

  • News

    CytoMed Therapeutics Refutes Recent Statements Regarding Inaccurate, Misleading Claims About Company's Research Programs, Clinical Progress, And Operations

  • Press releaseGlobe Newswire

    CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress

  • Press releaseGlobe Newswire

    CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India

  • News

    12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy

  • Press releaseGlobe Newswire

    CytoMed Therapeutics' Chairman Increases Effective Holdings to 21.95%

  • Press releasePRNewswire

    Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge

  • Press releaseGlobe Newswire

    CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.